Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Short Interest Down 5.1% in October

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) saw a large decrease in short interest during the month of October. As of October 31st, there was short interest totalling 11,790,000 shares, a decrease of 5.1% from the October 15th total of 12,420,000 shares. Based on an average daily volume of 1,120,000 shares, the days-to-cover ratio is currently 10.5 days.

Hedge Funds Weigh In On Citius Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the business. BNP Paribas Financial Markets boosted its holdings in shares of Citius Pharmaceuticals by 88.5% during the 1st quarter. BNP Paribas Financial Markets now owns 69,615 shares of the company’s stock valued at $62,000 after acquiring an additional 32,686 shares during the last quarter. Miller Investment Management LP boosted its holdings in Citius Pharmaceuticals by 99.3% in the third quarter. Miller Investment Management LP now owns 99,640 shares of the company’s stock worth $50,000 after purchasing an additional 49,640 shares during the last quarter. Point72 DIFC Ltd bought a new stake in Citius Pharmaceuticals in the 2nd quarter worth approximately $29,000. Arkadios Wealth Advisors raised its stake in Citius Pharmaceuticals by 33.3% during the 3rd quarter. Arkadios Wealth Advisors now owns 200,000 shares of the company’s stock valued at $100,000 after buying an additional 50,000 shares during the last quarter. Finally, Wealth Advisory Solutions LLC lifted its holdings in shares of Citius Pharmaceuticals by 33.1% during the 3rd quarter. Wealth Advisory Solutions LLC now owns 201,000 shares of the company’s stock valued at $101,000 after buying an additional 50,000 shares during the period. Hedge funds and other institutional investors own 16.88% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and set a $4.00 price target on shares of Citius Pharmaceuticals in a report on Tuesday, November 12th.

Citius Pharmaceuticals Price Performance

CTXR stock opened at $0.20 on Monday. The stock has a market capitalization of $36.15 million, a P/E ratio of -0.83 and a beta of 1.66. Citius Pharmaceuticals has a 1-year low of $0.19 and a 1-year high of $1.07. The business has a fifty day moving average price of $0.43 and a 200-day moving average price of $0.60.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.